-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion

PUBT·07/27/2026 06:03:34
Listen to the news
AstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion
  • AstraZeneca reported H1 2026 revenue of USD 30.67 billion, up 9% from a year earlier.
  • Reported EPS rose 4% to USD 3.60, while core EPS climbed 12% to USD 5.21.
  • Q2 revenue increased 6% to USD 15.38 billion; reported EPS rose 2% to USD 1.61.
  • H1 product sales grew 8% to USD 28.9 billion, while alliance revenue jumped 31% to USD 1.7 billion.
  • Management said it remains on track for its USD 80 billion total revenue ambition for 2030, despite the CARDIO-TTRansform outcome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202607270200BITN____UKPR__EN_20260727-BIT-1901-0) on July 27, 2026, and is solely responsible for the information contained therein.